PRACA ORYGINALNA
AUTOIMMUNOLOGICZNA CUKRZYCA DOROSŁYCH (LADA) – OPIS PRZYPADKU
 
Więcej
Ukryj
1
Z Katedry i Kliniki Chorób Wewnętrznych Uniwersytetu Medycznego w Lublinie
 
MONZ 2009;15(4):585–590
SŁOWA KLUCZOWE:
STRESZCZENIE ARTYKUŁU:
W artykule przedstawiono przypadek 50-letniego mężczyzny z autoimmunologiczną cukrzycą dorosłych uznawaną początkowo za cukrzycę typu 2. Obraz kliniczny oraz słaba reakcja na doustne leki hipoglikemizujące po upływie 6 miesięcy od rozpoznania cukrzycy nasunęły podejrzenie cukrzycy typu LADA.

Diabetes seldom causes significant diagnostic problems. The report presents a case of 50-year-old male with LADA diabetes (latent autoimmune diabetes in adults). In this case, late onset of diabetes and increased patient’s body weight were the cause of primary diagnosis of type 2 diabetes and treatment with oral antidiabetic drugs. Poor effectiveness of these drugs 6 months after diagnosis of diabetes, as well as the presence of autoimmune diseases in family members, were the reason to perform further diagnostic tests. Low concentration of C peptide and the presence of serum glutamic acid decarboxylase antibodies confirmed the diagnosis of LADA. The implementation of insulin therapy helped to restore and maintain normoglycaemia.
 
REFERENCJE (9):
1. Groop LC, Bottazzo GF, Doniac D. Islet cell antibodies identify latent type 1 diabetes in patients aged 35–75 years at diagnosis. Diabetes 1986; 35, 237-241.
2. Fourlanos S, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, Colman PG, Harrison LC.: Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia. 2005, 48, 2206-2012.
3. P. Myhill, W. A. Davis, D. G. Bruce, I. R. Mackay, P. Zimmet and T. M. E. Davis: Chronic complications and mortality in community-based patients with latent autoimmune diabetes in adults: the Fremantle Diabetes Study. Diabetic Medicine 2008, 25, 1245-1250.
4. Pozzilli P, Di Mario U.: Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention. Diabetes Care 2001, 24, 1460-1467.
5. Stenström G., Gottsäter A., Bakhtadze E., Berger B., Sundkvist G.: Latent autoimmune diabetes in adults, definition, prevalence, β-Cell function, and treatment. Diabetes 2005, 54, suppl.2, 68-72.
6. Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A, Nissen M, Ehrnstrom BO, Forsen B, Snickars B, Lahti K, Forsblom C, Saloranta C, Taskinen MR, Groop LC: Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 1999, 48, 150-157.
7. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR.: Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993, 42, 359-362.
8. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, Shattock M, Bottazzo GF, Holman R. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet. 1997, 350, 1288-1293.
9. Wroblewski M, Gottsater A, Lindgarde F, Fernlund P, Sundkvist G.: Gender, autoantibodies, and obesity in newly diagnosed diabetic patients aged 40-75 years. Diabetes Care 1998, 21, 250-255.
eISSN:2084-4905
ISSN:2083-4543